Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and left ventricular diastolic function in adults with type 2 diabetes
2016-001264-11Phase 4Completed
- Sponsor
- University Medical Center Mainz
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and left ventricular diastolic dysfunction (LVDD) comparing Empagliflozin plus usual care with Placebo plus usual care (2 arms). Primary endpoint: Change in E/E′ ratio from baseline to 12 weeks. Started Jun 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)left ventricular diastolic dysfunction (LVDD)
Beyond the preview
Go deeper on 2016-001264-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001264-11.